VC firm Vivo Capital outlays $740m for biotech investment Pharmaceutical Technology Vivo Capital secures $740M to invest in preclinical- and clinical-stage biotechs Fierce Biotech Vivo Capital Closes Opportunity Fund FIN News Vivo Capital closes on $740m for third cycle of evergreen public fund Venture Capital Journal Healthcare specialist Vivo Capital closes third Opportunity Fund cycle at $740m Alternatives Watch
Recent Comments